HAEMONETICS CORP — Director's Dealing 2020

Jun 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2020-06-12

Reporting Person: Burke William P. Mr. (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-12	Common Stock	A	22334	—	Acquired	35029	Direct
2020-06-12	Common Stock	S	197	$89.29	Disposed	34832	Direct
2020-06-15	Common Stock	S	9720	$87.71	Disposed	25112	Direct
2020-06-16	Common Stock	S	5259	$90.36	Disposed	19853	Direct
2020-06-16	Common Stock	S	6146	$91.38	Disposed	13707	Direct
2020-06-16	Common Stock	S	1209	$92.09	Disposed	12498	Direct

Footnotes

F1: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020.

F2: This number includes unvested restricted stock units ("RSUs") previously reported.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the
reporting person.

F5: Transaction pursuant to an existing 10b5-1 trading plan.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.94 to $90.94, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) through (8) to this Form 4.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.95 to $91.95, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.97 to $92.24, inclusive.